Adaptive Biotechnologies Corporation $ADPT Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC cut its position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 29.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 900,231 shares of the company’s stock after selling 373,415 shares during the period. Kennedy Capital Management LLC’s holdings in Adaptive Biotechnologies were worth $14,620,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. California State Teachers Retirement System grew its stake in shares of Adaptive Biotechnologies by 1.0% in the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after buying an additional 933 shares in the last quarter. Captrust Financial Advisors boosted its holdings in Adaptive Biotechnologies by 7.6% in the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after purchasing an additional 1,119 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Adaptive Biotechnologies by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock valued at $120,000 after purchasing an additional 1,532 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares during the period. Finally, Diversified Trust Co. boosted its holdings in Adaptive Biotechnologies by 5.6% in the fourth quarter. Diversified Trust Co. now owns 42,200 shares of the company’s stock valued at $685,000 after purchasing an additional 2,224 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ADPT shares. BTIG Research reiterated a “buy” rating and issued a $22.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. TD Cowen lifted their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Morgan Stanley decreased their target price on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Guggenheim reiterated a “buy” rating and issued a $21.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.57.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ ADPT opened at $17.60 on Monday. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of -53.33 and a beta of 2.16. The business has a 50-day moving average of $14.57 and a two-hundred day moving average of $15.65. Adaptive Biotechnologies Corporation has a 1 year low of $9.90 and a 1 year high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The company had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.Adaptive Biotechnologies’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.20) EPS. As a group, equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Insiders Place Their Bets

In other Adaptive Biotechnologies news, CFO Kyle Piskel sold 3,115 shares of Adaptive Biotechnologies stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $13.04, for a total transaction of $40,619.60. Following the completion of the sale, the chief financial officer directly owned 256,725 shares of the company’s stock, valued at $3,347,694. The trade was a 1.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $18.00, for a total value of $198,000.00. Following the sale, the insider directly owned 416,775 shares of the company’s stock, valued at $7,501,950. This trade represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 497,594 shares of company stock valued at $7,254,096 over the last quarter. Corporate insiders own 5.70% of the company’s stock.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.